L-dopa in uremic patients with the restless legs syndrome

Reuven Sandyk; Charles Bernick; Stanley M. Lee; Lawrence Z. Stern; Robert P. Iacono; Colin R. Bamford

doi:10.3109/00207458708987132

L-dopa in uremic patients with the restless legs syndrome

Reuven Sandyk, Charles Bernick, Stanley M. Lee, Lawrence Z. Stern, Robert P. Iacono, Colin R. Bamford

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Abstract

Restless legs syndrome (RLS) is a poorly understood, often distressing condition that is particularly prevalent among patients with chronic renal failure. A wide variety of medications have been used to treat RLS with variable results. In order to evaluate the efficacy of carbidopa/levodopa therapy, eight consecutive uremic patients with RLS on maintenance hemodialysis were treated with doses ranging from 25/100 to 25/250 twice daily. Six of eight patients obtained satisfactory relief which has continued for 3 months follow-up. Carbidopa/levodopa appears to be an effective option in management of RLS in patients with chronic renal failure.

Original language	English (US)
Pages (from-to)	233-235
Number of pages	3
Journal	International Journal of Neuroscience
Volume	35
Issue number	3-4
DOIs	https://doi.org/10.3109/00207458708987132
State	Published - 1987
Externally published	Yes

Keywords

Chronic renal failure
L-dopa
Restless legs syndrome

ASJC Scopus subject areas

General Neuroscience

Access to Document

10.3109/00207458708987132

Cite this

@article{986d9499392444d490b4a336cf12df91,

title = "L-dopa in uremic patients with the restless legs syndrome",

abstract = "Restless legs syndrome (RLS) is a poorly understood, often distressing condition that is particularly prevalent among patients with chronic renal failure. A wide variety of medications have been used to treat RLS with variable results. In order to evaluate the efficacy of carbidopa/levodopa therapy, eight consecutive uremic patients with RLS on maintenance hemodialysis were treated with doses ranging from 25/100 to 25/250 twice daily. Six of eight patients obtained satisfactory relief which has continued for 3 months follow-up. Carbidopa/levodopa appears to be an effective option in management of RLS in patients with chronic renal failure.",

keywords = "Chronic renal failure, L-dopa, Restless legs syndrome",

author = "Reuven Sandyk and Charles Bernick and Lee, {Stanley M.} and Stern, {Lawrence Z.} and Iacono, {Robert P.} and Bamford, {Colin R.}",

year = "1987",

doi = "10.3109/00207458708987132",

language = "English (US)",

volume = "35",

pages = "233--235",

journal = "International Journal of Neuroscience",

issn = "0020-7454",

publisher = "Informa Healthcare",

number = "3-4",

}

TY - JOUR

T1 - L-dopa in uremic patients with the restless legs syndrome

AU - Sandyk, Reuven

AU - Bernick, Charles

AU - Lee, Stanley M.

AU - Stern, Lawrence Z.

AU - Iacono, Robert P.

AU - Bamford, Colin R.

PY - 1987

Y1 - 1987

N2 - Restless legs syndrome (RLS) is a poorly understood, often distressing condition that is particularly prevalent among patients with chronic renal failure. A wide variety of medications have been used to treat RLS with variable results. In order to evaluate the efficacy of carbidopa/levodopa therapy, eight consecutive uremic patients with RLS on maintenance hemodialysis were treated with doses ranging from 25/100 to 25/250 twice daily. Six of eight patients obtained satisfactory relief which has continued for 3 months follow-up. Carbidopa/levodopa appears to be an effective option in management of RLS in patients with chronic renal failure.

AB - Restless legs syndrome (RLS) is a poorly understood, often distressing condition that is particularly prevalent among patients with chronic renal failure. A wide variety of medications have been used to treat RLS with variable results. In order to evaluate the efficacy of carbidopa/levodopa therapy, eight consecutive uremic patients with RLS on maintenance hemodialysis were treated with doses ranging from 25/100 to 25/250 twice daily. Six of eight patients obtained satisfactory relief which has continued for 3 months follow-up. Carbidopa/levodopa appears to be an effective option in management of RLS in patients with chronic renal failure.

KW - Chronic renal failure

KW - L-dopa

KW - Restless legs syndrome

UR - http://www.scopus.com/inward/record.url?scp=0023391259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023391259&partnerID=8YFLogxK

U2 - 10.3109/00207458708987132

DO - 10.3109/00207458708987132

M3 - Article

C2 - 3654080

AN - SCOPUS:0023391259

SN - 0020-7454

VL - 35

SP - 233

EP - 235

JO - International Journal of Neuroscience

JF - International Journal of Neuroscience

IS - 3-4

ER -

L-dopa in uremic patients with the restless legs syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this